The Small Biotech Innovation Act aims to create an exception for small biotech manufacturers from the Medicare drug price negotiation program. The main goal is to support innovation and research in the biotech sector, particularly for smaller companies that focus heavily on research and development. The key provisions of this act establish criteria for small biotech manufacturers to qualify for this exception. Starting in 2029, certain drugs produced by these manufacturers will not be subject to price negotiations if the manufacturers meet specific conditions.